The vaccine adjuvants market is projected to reach USD 1.6 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 1.7% during the forecast period. Growth in the vaccine adjuvants market can be attributed to factors such as the collaborations and partnerships among market players for the development of vaccine adjuvants and an increasing number of COVID-19 vaccines in the development pipeline
Download PDF Sample of This Strategic Report: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894
Vaccine adjuvants play a pivotal role in enhancing the efficacy of vaccines, promoting stronger immune responses, and extending the longevity of immune protection. The increasing prevalence of infectious diseases and the growing demand for improved vaccine formulations have fueled the growth of the vaccine adjuvants market worldwide.
Key Highlights of the Report:
Market Overview: The report provides a thorough analysis of the vaccine adjuvants market's current status, examining its historical performance and projecting future trends. It covers the key drivers, challenges, and opportunities shaping the market landscape.
Segmentation Analysis: The study offers a comprehensive segmentation analysis based on type, route of administration, application, and region. This allows stakeholders to identify high-growth segments and tailor their strategies accordingly.
Competitive Landscape: The report profiles prominent companies operating in the vaccine adjuvants industry. It highlights their product portfolios, recent developments, strategic initiatives, and key financials, offering insights into the competitive dynamics of the market.
Regional Analysis: Geographically, the market has been analyzed across key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The report evaluates the regional market attractiveness and growth potential.
The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market
The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets of the region is drive by increasing investments in the life sciences sector and rising awareness through conferences & symposiums, and growing emphasis on strategic initiatives such as partnerships, and collaborations by biopharma and biotech companies.
Emerging Trends and Future Outlook: The report identifies the emerging trends that are likely to shape the vaccine adjuvants market in the coming years. It also provides an outlook on the market's growth trajectory during the forecast period.
Access full Report Description, TOC, Table of Figure, Chart, etc: https://www.marketwatch.com/press-release/vaccine-adjuvants-market-worth-16-billion-size-prominent-players-and-key-figures-reviewed-in-latest-research-report-2022-2027-2023-04-24
Key Market Players
GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia)
GlaxoSmithKline (UK) held the leading position in the market. The company has entered into collaborations and partnerships with a number of vaccine developers and is recognized for its contrition in the COVID-19 space.
Recent Developments
- Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
- SK Bioscience (South Korea)and GSK plc (UK)entered into a collaboration for COVID-19 vaccine development.
Enquiry Before Buying this Report : https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=152603894
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Media Contact
Company Name: MarketsandMarkets(TM) Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States